However, its crucial to remember that Semaglutide GLP-1 is not suitable for everyone
GIP receptor agonism is hypothesised, based on preclinical and early clinical data, to complement GLP-1 effects on insulin secretion and may influence adipose tissue metabolism, though the precise contribution in humans remains an area of active investigation
Exenatide is administered via a pre-filled subcutaneous injection device at a dose of 5 or 10 mcg twice daily, within 60 minutes before morning and evening Current approved indications are add on to metformin, sulfonylurea, thiazolidinedione, a combination of metformin and a sulfonylurea, or a combination of metformin and a thiazolidinedione
Retatrutide is not currently FDA-approved and is not commercially available through ordinary prescribing, telehealth, retail pharmacy, compounding pharmacy, or direct-to-consumer purchase
For once-weekly preparations , NHS guidance emphasises choosing a convenient day of the week and maintaining that schedule
References Frias JP, Davies MJ, Rosenstock J, et al
